New quadruple therapy targets liver cancer and diabetes together
NCT ID NCT07557914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (epalrestat, HAIC, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can control the cancer for at least 12 months without major side effects. About 32 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A simple card game could transform diabetes care